Alaunos Therapeutics, Inc.
Moat Score — Alaunos Therapeutics, Inc.
Total Moat Score
2 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | Alaunos's historical moat was its licensed Sleeping Beauty gene-transfer platform and NCI/MD Anderson TCR library, but it terminated the Precigen license in 2024 and the core patent expires in 2026; its new ALN1001 obesity candidate is unpatented and pre-clinical, leaving almost no durable IP protection today. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | With one full-time employee and reliance on outsourced manufacturing and consultants, Alaunos has no scale, process, or cost advantage versus any competitor; it is a sub-scale operation by necessity, not strategy. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | The company has no approved product and no revenue, so it has no pricing power of any kind; any future pricing power is purely hypothetical and years away, if ever realized. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Nothing about TCR-T cell therapy manufacturing or an early obesity candidate generates network effects; value does not compound with more patients or partners in any structural sense. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Its remaining relationships (NCI collaboration, MD Anderson trial site, FDA dialogue to close the TCR-T trial) create minor institutional switching costs for a potential acquirer, but there are no customers or users with anything to switch away from. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Alaunos's Houston cGMP manufacturing facility was built for a now-discontinued TCR-T program and is not sized or utilized efficiently for its new obesity focus, offering no efficient-scale deterrent to entrants. |